eGFR, cystatin C and creatinine in shrunken pore syndrome

Hua Zhou; Min Yang; Xiaozhou He; Ning Xu

doi:10.1016/j.cca.2019.08.001

eGFR, cystatin C and creatinine in shrunken pore syndrome

Clin Chim Acta. 2019 Nov:498:1-5. doi: 10.1016/j.cca.2019.08.001. Epub 2019 Aug 6.

Authors

Hua Zhou¹, Min Yang¹, Xiaozhou He², Ning Xu³

Affiliations

¹ Department of Nephrology, The Third Affiliated Hospital of Soochow University, 213003 Changzhou, China.
² Department of Urology, The Third Affiliated Hospital of Soochow University, 213003 Changzhou, China. Electronic address: hexiaozhou911@yeah.net.
³ Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, 22185 Lund, Sweden. Electronic address: ning.xu@med.lu.se.

PMID: 31398310
DOI: 10.1016/j.cca.2019.08.001

Abstract

Shrunken pore syndrome (SPS) is a condition in which the estimated glomerular filtration rate (eGFR) based on serum/plasma cystatin C concentration is significantly lower than the eGFR based on creatinine. According to the literatures, the diagnosis of SPS could be defined when the eGFR_{cystatin C} is <70% of eGFR_creatinine. Although the incidence of SPS varies in different patient populations and healthy seniors, it has been demonstrated that patients with SPS have poor prognosis. The present review has summarized its diagnosis, epidemiology, prognosis and possible pathophysiology basis. Moreover, we discuss the prevention and treatment of SPS in clinical practice as future challenges.

Keywords: Creatinine; Cystatin C; Glomerular filtration rate; Shrunken pore syndrome.

Publication types

Review

MeSH terms

Creatinine / blood*
Cystatin C / blood*
Glomerular Filtration Rate*
Humans
Kidney Diseases / diagnosis*
Kidney Diseases / epidemiology
Kidney Diseases / physiopathology
Kidney Diseases / therapy
Prognosis
Syndrome

Substances

Cystatin C
Creatinine